Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience
oleh: Abdul Muqtadir Abbasi, Mohammad Usman Shaikh, Natasha Ali, Maria Khan, Salman Muhammad Soomar
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2022-01-01 |
Deskripsi
Eltrombopag has been used in ITP and found its use in AA armamentarium recently.We retrospectively analyzed 61 patients at a tertiary care center in Pakistan from January 2015 to January 2021. They included patients with severe AA who were refractory to at least one course of immunosuppressive therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI issues were notable.We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA.